Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.33 |
| ▸ | REN | P00797 | 3/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 6/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168362 | 1.00 | ACE (0.33) | ACERENBMP1VSIRCD274 | |
| SCHEMBL21168352 | 0.95 | VSIR (0.35) | ACERENBMP1VSIRCD274 | |
| SCHEMBL21168353 | 0.95 | VSIR (0.35) | ACERENBMP1VSIRCD274 | |
| SCHEMBL21168342 | 0.95 | VSIR (0.35) | ACERENBMP1VSIRCD274 | |
| SCHEMBL21168290 | 0.94 | FABP4 (0.32) | RENBMP1VSIRCD274FKBP1A | |
| SCHEMBL21168289 | 0.94 | FABP4 (0.32) | RENBMP1VSIRCD274FKBP1A | |
| SCHEMBL25476866 | 0.94 | VSIR (0.33) | BMP1VSIRCD274FKBP1AITGB3 | |
| SCHEMBL21168299 | 0.93 | ACE (0.36) | ACERENBMP1FABP4FABP5 | |
| SCHEMBL21168320 | 0.93 | ACE (0.36) | ACERENBMP1FABP4FABP5 | |
| SCHEMBL31489982 | 0.93 | ACE (0.36) | ACERENBMP1FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-01-24 | — | — | US | disclosed |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2021-05-13 | — | — | US | disclosed |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | CD47, HIF1AN, PIK3R5 | ACE 4818/4885REN 4264/4885BMP1 600/4885 |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | ACE 4811/4885REN 4143/4885BMP1 593/4885 |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | ACE 4811/4885REN 4143/4885BMP1 593/4885 |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | CD47, HIF1AN, PIK3R5 | ACE 4810/4885REN 4116/4885BMP1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.